Fig. 1. Innate lymphoid cells infiltrate murine and human melanoma tumors.

a and b, Analyses of skin, tumors and lymph nodes of BRAF^CA;PTEN^loxp;Tyr::CreER^T2 mice. a, Number of NK cells, ILC1, ILC2 and ILC3 within skin and tumors. Skin was collected from the flank on the opposite side to tumor induction. Data pooled from 4 independent experiments (n=14 mice; 2-5 mice/experiment). b, Number of NK cells, ILC1, ILC2 and ILC3 from control, non-invaded and tumor-invaded axillary and inguinal lymph nodes (LN). Control axillary and inguinal LN were collected from naïve mice. LN identified as being tumor-invaded were black and hyperplasic; non-invaded LN were white and similar in size to control LN. Data pooled from 4 independent experiments (n=16-19 mice; 2-5 mice/group/experiment). c, Multiplex immunohistochemistry staining of human primary melanoma tumors. Representative multiplex immunohistochemistry staining of primary melanoma tumor with ILC2 infiltration (left, scale bar 50 μm). Inset, magnified tumor infiltrated ILC2 is shown (scale bar, 10 μm). ILC2 were identified as CD45⁺CD3^-GATA3⁺. Density and frequency of ILC2 in primary melanoma tumors (right). d, Frequency of NK cells, ILC1, ILC2 and ILC3 in ten human melanoma metastatic tumors as identified using the gating strategy provided in Supplementary Fig. 4 by mass cytometry. Patient characteristics relating to c and d are detailed in Supplementary Table 1. a-d, Each circle represents one mouse or human sample and data show the mean ± s.e.m. a and b, Statistical analyses were performed using paired (a) or ANOVA with Tukey’s multiple comparison test (b). p-values are indicated.